REFERENCES
- Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32(Suppl 5)S112–119, [INFOTRIEVE], [CSA]
- Cheung AK, Sarnak MJ, Guofen Y, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353–362, [INFOTRIEVE], [CSA], [CROSSREF]
- Racki S, Zaputovic L, Vujicic B, Mavric Z, Grzetic M, Ravlic-Gulan J. Cardiovascular risk factors and diseases strongly predict hemodialyis treatment outcome in maintenance hemodialysis patients. Croat Med J 2005; 46(6)936–941, [INFOTRIEVE], [CSA]
- Stenvinkel P. Inflammation in end-stage renal disease—a fire that burns within. Cardiovascular Disorders in Hemodialysis, C Ronco, A Brendolan, NW Levin. Karger, Basel 2005; 185–199
- Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307–1320, [INFOTRIEVE], [CSA]
- Eknoyan G, Beck GJ, Cheung AK, , for the Hemodialysis (HEMO) Study Group, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010–2019, [INFOTRIEVE], [CSA], [CROSSREF]
- Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524–1538, [INFOTRIEVE], [CSA], [CROSSREF]
- Tracy RP. Inflammation in cardiovascular disease. Circulation 1998; 97: 2000–2002, [INFOTRIEVE], [CSA]
- Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115–126, [INFOTRIEVE], [CSA], [CROSSREF]
- Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodialysis Int 2004; 8: 118–129, [CSA], [CROSSREF]
- Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practise. A statement for healthcare professionals from the Centres for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511, [INFOTRIEVE], [CSA], [CROSSREF]
- Stenvinkel P, Alvestrand P. Inflammation in end-stage renal disease: Sources, consequences and therapy. Semin Dial 2002; 15: 329–337, [INFOTRIEVE], [CSA], [CROSSREF]
- Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNFα: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney Int 2005; 67: 1216–1233, [INFOTRIEVE], [CSA], [CROSSREF]
- Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469–476, [INFOTRIEVE], [CSA]
- Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999; 14: 1956–1960, [INFOTRIEVE], [CSA], [CROSSREF]
- Nascimento MN, Pecoits-Filho R, Qureshi AR, et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant 2004; 19: 2803–2809, [INFOTRIEVE], [CSA], [CROSSREF]
- Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition and atherosclerosis in chronic renal patients. Kidney Int 1999; 55: 1899–1911, [INFOTRIEVE], [CSA], [CROSSREF]
- Baudner S, Dali F. Standardization of the measurement of 14 proteins in human serum based on the new IFCC/BCR/CAP international reference material CRM 470. J Lab Med 1996; 20: 145–152, [CSA]
- Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997; 43: 52–58, [INFOTRIEVE], [CSA]
- Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 1971; 31: 87–96, [INFOTRIEVE], [CSA], [CROSSREF]
- Painter PC, Cope JY, Smith JL. Reference information for the clinical laboratory. Tietz Textbook of Clinical Chemistry, CA Burtis, ER Ashwood. WB Saunders Company, Philadelphia 1999; 1800
- Depner T, Beck B, Daugirdas J, Kusek J, Eknoyan G. Lessons from the hemodialysis (HEMO) study: an improved measure of the actual hemodialysis dose. Am J Kidney Dis 1999; 33: 142–149, [INFOTRIEVE], [CSA]
- Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1615–1617, [CSA], [CROSSREF]
- Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766–772, [INFOTRIEVE], [CSA], [CROSSREF]
- Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54: 627–636, [INFOTRIEVE], [CSA], [CROSSREF]
- Chauveau P, Level C, Lasseur C, et al. C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: a two-year prospective study. J Ren Nutr 2003; 13: 137–143, [INFOTRIEVE], [CSA], [CROSSREF]
- Tellingen A, Grooteman MPC, Schoorl M, et al. Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int 2002; 62: 632–638, [INFOTRIEVE], [CSA], [CROSSREF]
- Tsirpanlis G, Bagos P, Ioannou D, et al. The variability and accurate assessment of microinflammation in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 150–157, [INFOTRIEVE], [CSA], [CROSSREF]
- Ockene IR, Matthews CE, Rifai N, et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001; 47: 444–450, [INFOTRIEVE], [CSA]
- Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648–658, [INFOTRIEVE], [CSA], [CROSSREF]
- Korevaar JC, Manen JG, Dekker FW, Waart DR, Boeschoten EW, Krediet RY, for the NECOSAD study group. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 2004; 15: 2916–2922, [INFOTRIEVE], [CSA], [CROSSREF]
- National Kidney Foundation. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35(6, Suppl. 2)1–140, [CSA]